Menu
Back to User profile » Dr Yoshiro Nakahara
Papers published by Dr Yoshiro Nakahara:
Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring BRAF V600E Mutation
Yagami Y, Nakahara Y, Manabe H, Yamamoto H, Otani S, Sato T, Igawa S, Kubota M, Sasaki J, Naoki K
OncoTargets and Therapy 2022, 15:1369-1374
Published Date: 11 November 2022
A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
Igawa S, Kasajima M, Ono T, Ozawa T, Kakegawa M, Kusuhara S, Sato T, Nakahara Y, Fukui T, Yokoba M, Kubota M, Mitsufuji H, Sasaki J, Naoki K
Cancer Management and Research 2021, 13:8695-8705
Published Date: 20 November 2021
Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease
Igawa S, Nishinarita N, Takakura A, Ozawa T, Harada S, Kusuhara S, Niwa H, Hosotani S, Sone H, Nakahara Y, Fukui T, Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Sasaki J, Naoki K
Cancer Management and Research 2018, 10:7013-7019
Published Date: 14 December 2018
Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer
Shirasawa M, Fukui T, Kusuhara S, Hiyoshi Y, Ishihara M, Kasajima M, Nakahara Y, Otani S, Igawa S, Yokoba M, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K
Cancer Management and Research 2018, 10:6039-6047
Published Date: 21 November 2018
Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1
Nakahara Y, Takagi Y, Hosomi Y, Kagei A, Yamamoto T, Sawada T, Yomota M, Okuma Y, Mikura S, Okamura T
OncoTargets and Therapy 2016, 9:5287-5295
Published Date: 24 August 2016